Clinical trial · Interventional
Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery
Addition of Dexmedetomidine to Ropivacaine for Ultrasound Guided Erector Spinae Block: Evaluation of Effect on Postoperative Pain After Breast Surgery: A Double-Blinded, Prospective, Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients undergoing Partial or total mastectomy with axillary LN dissection will receive prior to induction of general anaesthesia ESP block at T4 level at the same side of the surgery. one group will receive ropivacaine 0.375% and the other will get ropivacaine 0.375% with dexmedetomidine 0.5mcg/kg as an adjuvant. time to first narcotic requirement will be documented and therefore an assessment of the duration of action of the block will be made
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Axillary Lymph Node Dissection | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Mastectomy | — | UNRESOLVED | — |
| Pain, Postoperative | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Precedex
- description
- participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation
- interventionNames
- Drug: Dexmedetomidine
- type
- EXPERIMENTAL
- label
- Dexmedetomidine
- description
- participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation
- interventionNames
- Drug: Dexmedetomidine
Primary outcomes (1)
- measure
- Pain assessment in the first 24 hours post operatively: VAS score
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. ASA class I, II and III patients 2. Age range: 18-80 years old 3. Elective partial or unilateral radical mastectomy with sentinel lymph node dissection Exclusion Criteria: 1. Pregnant woman 2. Bilateral mastectomy. 3. Skin infection at the site of needle puncture 4. Coagulopathy problems 5. Allergy or contraindication to any of the study drugs 6. Recent use of opioid drugs
References
Publications (0)
Data not yet available